Nucana Plc (NCNA) - News Archive

: This article aims to present an analysis of the latest findings regarding NUC-7738, a promising therapeutic modality developed by Nucana Plc, as showcased at the ESMO Congress 2025. The article will shed light on the...

In a significant development for oncology, NuCana plc has announced encouraging preliminary data from their ongoing clinical trials investigating NUC-3373, a novel chemotherapy agent designed to treat various cancers, s...

In the venerated halls of scientific inquiry and pharmaceutical advancement, there emerges a beacon of promise as NuCana plc, that eminent biopharmaceutical entity headquartered in the fair city of Edinburgh, recently p...

As the fight against melanoma continues, innovative therapeutic combinations are critical for managing patients who are refractory or resistant to existing treatments. Nucana Plc s recent presentation at the ESMO Congre...

NuCana Plc has recently taken a critical step in its clinical development strategy by announcing the discontinuation of its Phase 2 randomized colorectal cancer study, referred to as NuTide:323. This decision follows a...

NuCana Regains Compliance with Nasdaq Minimum Bid Price RequirementNuCana plc, a pharmaceutical company based in Edinburgh, United Kingdom, has announced that it has regained compliance with the minimum bid price requir...

NuCana plc, a pharmaceutical company based in Edinburgh, United Kingdom, recently announced a significant change that will have a profound impact on its shareholders. The company has successfully altered the ratio of it...

NuCana plc Announces Change in ADS Ratio: Impact on Shareholders and Market PerformanceEDINBURGH, United Kingdom, March 27, 2024 - NuCana plc (NASDAQ: NCNA) recently revealed its plans to adjust the ratio of its America...

NUC-3373 Demonstrates Encouraging Results in Colorectal Cancer TreatmentIn a recent press release, NuCana Plc presented promising data on its investigational drug NUC-3373 at the AACR-NCI-EORTC International Conference...